Stay up to date

News

see all news
Clinical data published of a novel serum biomarker quintet that improves disease prognosis in men with confirmed prostate cancer

November 18, 2021

Proteomedix presents at the annual congress of the Italian Society of Urology in Riccione and the Society of Urologists in Private Hospitals in Modena.

October 14, 2021

Publications

see all publications
The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer.

Morote J, Campistol M, Celma A, Regis L, de Torres I, Semidey ME, Roche S, Mast R, Santamaría A, Planas J, Trilla E. World J Mens Health. 2021 Dec 27. doi: 10.5534/wjmh.210117.

A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology

Athanasiou A, Tennstedt P, Wittig A, Huber R, Straub O, Schiess R, Steuber T. PLoS One. 2021 Nov 12;16(11):e0259093.

Events

see all events
Mar 18th-21st, 2022 - Annual EAU Congress

Amsterdam, NL

Sep 9-10th, 2022 - Imperial Prostate Materclass

London, UK

Resources

see all resources
Application note - Implementation of Proclarix in the workflow of a clinical laboratory
Analytical validation of the Proclarix Risk Score for the diagnosis of prostate cancer
Analytical performance of automated thrombospondin-1 and cathepsin D immunoassays for prostate cancer risk assessment